Q3 2016 13F Holders as of 9/30/2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
161
-
Total 13F shares, excl. options
-
106M
-
Shares change
-
+1.02M
-
Total reported value, excl. options
-
$1.28B
-
Value change
-
+$17.3M
-
Put/Call ratio
-
0.38
-
Number of buys
-
71
-
Number of sells
-
-73
-
Price
-
$12.08
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2016
200 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q3 2016.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 161 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 106M shares
of 124M outstanding shares and own 85.73% of the company stock.
Largest 10 shareholders include Third Security, LLC (19.3M shares), IRIDIAN ASSET MANAGEMENT LLC/CT (9.29M shares), VANGUARD GROUP INC (8.2M shares), FMR LLC (7.81M shares), First Eagle Investment Management, LLC (7.4M shares), BB BIOTECH AG (7.38M shares), BlackRock Fund Advisors (4.52M shares), STATE STREET CORP (3.26M shares), BlackRock Institutional Trust Company, N.A. (3.01M shares), and JPMORGAN CHASE & CO (2.98M shares).
This table shows the top 161 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.